Connect Biopharma Holdings Limited (CNTB)

Market Cap	74.90M
Revenue (ttm)	n/a
Net Income (ttm)	-59.50M
Shares Out	55.10M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	1.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,123
Open	1.450
Previous Close	1.390
Day's Range	1.330 - 1.450
52-Week Range	0.535 - 2.840
Beta	-0.60
Analysts	Strong Buy
Price Target	6.50 (+381.13%)
Earnings Date	Apr 16, 2024

About CNTB

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise C...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 19, 2021
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: CNTB

Financial Performance

Financial numbers in CNY

Analyst Forecast

According to 2 analysts, the average rating for CNTB stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 381.13% from the latest price.

Price Target

$6.5

(381.13% upside)

Analyst Consensus: Strong Buy